We still have no idea why Stuart Ashman "resigned" fromSkinbiotherapeutics (SBTX) on Thursday night. What we do know is that he had already been suspended by the board as part of an investigation into his conduct. The question AIM Regulation should be asking is when the investigation/suspension started and has the company breached AIM Rule 10. I have written to my pals the Oxymorons at AIM Regulation
on Tom Winnifrith | Comments